ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
OKYO Pharma Ltd

OKYO Pharma Ltd (OKYO)

1.585
-0.02
(-0.94%)
Closed July 18 4:00PM
1.585
0.00
( 0.00% )
Pre Market: 7:00AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.585
Bid
1.50
Ask
1.66
Volume
2
0.00 Day's Range 0.00
1.09 52 Week Range 3.07
Market Cap
Previous Close
1.585
Open
-
Last Trade
2
@
1.63
Last Trade Time
08:00:00
Financial Volume
-
VWAP
-
Average Volume (3m)
20,524
Shares Outstanding
25,519,880
Dividend Yield
-
PE Ratio
-3.66
Earnings Per Share (EPS)
-0.43
Revenue
-
Net Profit
-11.01M

About OKYO Pharma Ltd

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chroni... OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain. Show more

Sector
Pharmaceutical Preparations
Industry
Miscellaneous Metal Ores,nec
Headquarters
Guernsey, Gbr
Founded
2018
OKYO Pharma Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker OKYO. The last closing price for OKYO Pharma was $1.59. Over the last year, OKYO Pharma shares have traded in a share price range of $ 1.09 to $ 3.07.

OKYO Pharma currently has 25,519,880 shares outstanding. The market capitalization of OKYO Pharma is $40.45 million. OKYO Pharma has a price to earnings ratio (PE ratio) of -3.66.

OKYO Latest News

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to...

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye...

OKYO Pharma Announces Participation in May 2024 Investor Conferences

LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0553.594771241831.531.661.42395591.5843174CS
40.35528.86178861791.231.661.09277941.46312553CS
120.1258.561643835621.461.661.09205241.45994963CS
26-0.085-5.089820359281.671.91.09941581.6053941CS
520.41435.35439795051.1713.071.091453852.09204555CS
156-2.915-64.77777777784.570.92011668282.51124414CS
260-2.915-64.77777777784.570.92011668282.51124414CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AUGXAugmedix Inc
$ 2.27
(147.71%)
3.18M
HUBCWHub Cyber Security Ltd
$ 0.0345
(94.92%)
62
SXTP60 Degrees Pharmaceuticals Inc
$ 0.4421
(79.72%)
29.18M
SERVServe Robotics Inc
$ 4.31
(63.88%)
9.63M
XWELXWELL Inc
$ 2.27
(26.11%)
36
SILOSilo Pharma Inc
$ 2.7201
(-21.61%)
4.74M
KITTNauticus Robotics Inc
$ 0.1011
(-21.57%)
2.64M
DHCDiversified Healthcare Trust
$ 2.61
(-16.35%)
9.13k
MTEMMolecular Templates Inc
$ 1.21
(-15.38%)
1
PLUGPlug Power Inc
$ 2.56
(-12.33%)
3.01M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.44215
(79.74%)
29.18M
SERVServe Robotics Inc
$ 4.2903
(63.13%)
9.62M
SGDSafe and Green Development Corporation
$ 0.3914
(5.84%)
8.02M
MAXNMaxeon Solar Technologies Ltd
$ 0.2298
(-4.41%)
5.98M
SQQQProShares UltraPro Short QQQ
$ 8.19
(-0.49%)
5.31M

OKYO Discussion

View Posts
glenn1919 glenn1919 1 week ago
OKYO............................https://stockcharts.com/h-sc/ui?s=OKYO&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 months ago
OKYO under $2
👍️0
Pisd Pisd 3 months ago
...loading zone OKYO$$ imo, $1.30's, glta...
👍️0
TIMGZ TIMGZ 4 months ago
CONFIRMED REPEATED NEWS, SAME HAPPENED WITH BNOX YESTERDAY******MARKET WILL DICTATE WAY FORWARD*****TREAD CAREFULLY

HAPPY WEEKEND TO YOU AND YOURS***GREETINGS
👍️0
TheFinalCD TheFinalCD 4 months ago
okyo 1.99 news OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 $OKYO https://t.co/tgjKEzE3jP— Health Stocks News (@health_stocks) March 22, 2024
👍️0
Monksdream Monksdream 4 months ago
OKYO under $2
👍️0
Monksdream Monksdream 4 months ago
OKYO 10Q due March 14
👍️0
Monksdream Monksdream 4 months ago
OKYO 10Q due March 7
👍️0
Monksdream Monksdream 5 months ago
OKYO under $2
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
EXIT...LOOKS LIKE DILUTION INTO NEWS
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
OKYO DAY TRADER
👍️0
subslover subslover 5 months ago
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical need
The initial trial of OK-101 to treat NCP is designed as a randomized, placebo-controlled, double-masked Phase 2 clinical trial and is planned to begin in 2Q 2024
NCP is an Orphan disease as listed in the National Organization for Rare Disorders
LONDON and NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared OK-101 as its first Investigational New Drug (IND) application for the treatment of NCP.

Notably, the initial IND submission to FDA proposed an open-label design for the clinical trial. Based on positive feedback from FDA, the Phase 2 study is now designed as a double-masked, randomized, 12-week placebo-controlled trial comparing OK-101 to placebo in NCP patients. A total of 54 patients are planned for the study, with NCP disease confirmed via confocal microscopy. The primary endpoint will be measured utilizing VAS pain relief scores. These protocol changes will enable a statistically valid demonstration of a true drug effect of OK-101 on NCP symptoms. OKYO Pharma is scheduling this trial to begin in Q2 2024.

The OK-101 trial, designed as a single-center trial, will be led by Pedram Hamrah, MD, of Tufts Medical Center, as Principal Investigator. Dr. Hamrah is Professor and Vice Chair of Research and Academic Programs, Co-Director of the Cornea Service and Director of the Center for Translational Ocular Immunology at Tufts Medical Center. An ophthalmologist and a clinician-scientist, Dr. Hamrah is a leading expert in NCP and co-inventor on the OK-101 patent. He is also a member of OKYO’s Scientific Advisory Board.

“I am very pleased that we have gained FDA IND clearance for the first drug to be tested for NCP, a debilitating disease,” said Dr. Hamrah. “Receiving the IND clearance in an important and novel indication was not a trivial hurdle to overcome. Now that the path has been opened for drugs to be tested in NCP, I am looking forward to working with the OKYO team to launch this important trial.”

“We are pleased to gain IND clearance for OK-101 to treat NCP as a second important disease target for the Company,” said Dr. Gary S. Jacob, CEO of OKYO. “OK-101 recently demonstrated favorable tolerability in a Phase 2 trial of dry eye patients along with statistically significant improvements in dry eye symptoms such as stinging/burning and blurred vision, which are also hallmarks of NCP. OK-101 was also shown in a cutting-edge mouse model of NCP to significantly reduce ocular neuropathic pain. We are looking forward to advancing OK-101 to potentially treat NCP, a chronically painful ocular disease with no FDA-approved therapy and a major unmet medical need for patients suffering from this condition.”
👍️0
Awl416 Awl416 5 months ago
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
👍️0
Sirpeter Sirpeter 8 months ago
Early still here
👍️0
Pisd Pisd 9 months ago
..bailed w a profit lol ...
👍️0
Sirpeter Sirpeter 9 months ago
I don't remember what $2 looks like
👍️0
tat4tat tat4tat 9 months ago
Really, looks like 2 bucks.
👍️0
Sirpeter Sirpeter 9 months ago
bet the first time that ever happened to you ...lol
👍️0
Pisd Pisd 9 months ago
..frustrating..Had limit order $3.05..now $2ish, important cure, OKYO$..gl...
👍️0
Sirpeter Sirpeter 9 months ago
Amazing...clinical trial is favorable but pps keeps going down...go figure
👍️0
mfayman mfayman 9 months ago
Big volume, just needed to take a breathe before we move further up the ladder imo
👍️0
Sirpeter Sirpeter 9 months ago
Will end up green today
👍️0
Sirpeter Sirpeter 9 months ago
Will be over $3 by Monday...
👍️0
Sirpeter Sirpeter 9 months ago
Got to add down here...could be a $75-100 play before Y/E
👍️0
Pisd Pisd 9 months ago
..thought it make $3..sell the news, terrible.. OKYO$...
👍️0
Sirpeter Sirpeter 9 months ago
Got some $2.35s...deal
👍️0
Sirpeter Sirpeter 9 months ago
Bought more this morning...luv sales
👍️0
Pisd Pisd 9 months ago
https://ih.advfn.com/stock-market/NASDAQ/okyo-pharma-OKYO/stock-news/92205380/form-6-k-report-of-foreign-issuer-rules-13a-16
👍️0
mfayman mfayman 9 months ago
Looks like we're seeing it $$ been a phenomenal week
👍️0
Ryguy008 Ryguy008 9 months ago
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")

https://www.globenewswire.com/news-release/2023/10/05/2755253/0/en/OKYO-Pharma-Announces-Positive-Safety-Data-Profile-for-the-ongoing-OK-101-Phase-2-Clinical-Trial-to-Treat-Dry-Eye-Disease-DED.html

$OKYO
👍️0
mfayman mfayman 9 months ago
Up to 3.5$ pre market this morning let's go !! OKYO
👍️0
mfayman mfayman 9 months ago
3$+ is the next stop
👍️0
mfayman mfayman 9 months ago
Nice little ore market action
👍️0
Cameo Brien Cameo Brien 9 months ago
$OKYO Video - Corporate Profile on OKYO Pharma Ltd (Nasdaq: OKYO)
👍️0
mfayman mfayman 9 months ago
Excellent close!! Once 2.50 broke that was it
👍️0
Cameo Brien Cameo Brien 9 months ago
https://news.squeezereport.com/short-squeeze/okyo-pharma-limited-nasdaq-okyo-short-squeeze-2023-10-04/
👍️0
Cameo Brien Cameo Brien 9 months ago
Loaded
👍️0
Sirpeter Sirpeter 9 months ago
Heading to $3
👍️0
Ryguy008 Ryguy008 9 months ago
Looking great!

$OKYO
👍️0
mfayman mfayman 9 months ago
First half of the week price action is Right on Target $$
👍️0
mfayman mfayman 9 months ago
Another big volume day like yesterday we're moving $$
👍️0
mfayman mfayman 9 months ago
Once we break 2.50 clear skies to 3$ imo
👍️0
mfayman mfayman 9 months ago
Were primed, loving the activity here last couple days!
👍️0
Cameo Brien Cameo Brien 9 months ago
Get some
👍️0
mfayman mfayman 10 months ago
Seeing that next leg up here $
👍️0
mfayman mfayman 10 months ago
Killer volume today!
👍️0
Cameo Brien Cameo Brien 10 months ago
Hey now
👍️0
Cameo Brien Cameo Brien 10 months ago
Lfg
👍️0
Sirpeter Sirpeter 10 months ago
Looks like we're OK-yo!...
👍️0
mfayman mfayman 10 months ago
Boom 2+$ solid day so far
👍️0

Your Recent History

Delayed Upgrade Clock